Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512194 · ClinicalTrials.gov registry record · Phase 2
Investigation to Understand and Optimize Psilocybin
A Phase 2 study of Depression, sponsored by Charles Raison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT06512194 is a Phase 2 study of Depression that is actively recruiting participants, run by Charles Raison. The registered enrollment target is 141 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06512194, a Phase 2 study of Depression, is actively recruiting participants, sponsored by Charles Raison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.
Conditions Studied
Interventions
- DRUG Psilocybin
- DEVICE Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- DEVICE Sham taVNS
Study Locations (1)
Colorado
- Vail Health Behavioral Health - Edwards
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06512194
The ClinicalTrials.gov registry entry for NCT06512194 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (82% lower). The listed sponsor is Charles Raison, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Psilocybin is the first listed.
NCT06512194 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06512194 about?
NCT06512194 is a clinical study titled "Investigation to Understand and Optimize Psilocybin". This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS),...
What is the current status of trial NCT06512194?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2025-05-13. Estimated completion is 2029-05.
What conditions does trial NCT06512194 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06512194?
The interventions under investigation include: Psilocybin (DRUG), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) (DEVICE), Sham taVNS (DEVICE).
Who is sponsoring clinical trial NCT06512194?
This trial is sponsored by Charles Raison, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512194 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.